Archiv
Study finds hope for oral hepatitis C regimen
A study published in the New England Journal of Medicine found that 36% of hepatitis C patients who took the oral drug candidates daclatasvir and asunaprevir had undetectable viral loads after 24 weeks. Meanwhile, nine in 10...[подробнее]
Creutzfeldt-Jakob disease test available, U.K. tells neurologists
British neurologists have been told by the National Health Service that the first noninvasive test for Creutzfeldt-Jakob disease is available. A researcher says it could help guide risk management strategies for safeguarding the...[подробнее]
First clinical trial site initiated in CSL Behring Phase II/III pivotal study of recombinant fusion protein linking coagulation factor IX with recombinant albumin
Source:...[подробнее]
Test data show potency of drug candidate for hepatitis C
Idenix Pharmaceuticals reported interim data from a Phase IIb trial showing that its lead hepatitis C agent reduced viral load to an undetectable level after 28 days in 73% of patients given a 100-milligram dose and 63% of those...[подробнее]
Trial opens door for more testing of hepatitis C vaccine
British researchers used an adenoviral vector strategy to develop a vaccine that can strengthen T cells' response against the hepatitis C virus. The study, published in the journal Science Translational Medicine, found the...[подробнее]
Clinical study begins for experimental hemophilia drug
Pfizer launched an early-stage trial of PF-05280602, a modified recombinant factor VIIa for prophylactic and acute treatment of hemophilia. The move represents a milestone payment for Catalyst Biosciences, the compound's...[подробнее]
FDA expedites review of hepatitis C drug
The FDA granted fast-track designation to Achillion Pharmaceuticals' ACH-1625 as a treatment for hepatitis C. The compound is undergoing Phase II testing. Reuters
Source: AABBsmartbrief[подробнее]
Displaying 1 to 7 of 9
- 1
- 2
- следующ. >